Research bundles
Starter Bundle
Low stock
Order within — to ship today
Arrives 26 – 30 November to Europe
Starter Bundle
Original price was: 244,12 €.194,20 €Current price is: 194,20 €.
Bring metabolic-signalling and copper-peptide research into one straightforward selection. Starter pairs retatrutide with GHK-Cu in clearly listed vial quantities, with BAC Water included. Spend less time assembling separate products and see your complete bundle value before you order.
Every compound, clearly identified
Specifications
Retatrutide · 10 mg
Molecular profile
- Sequence
- Y-Aib-QGTFTSDYSI-alphaMeLeu-LDKK(AEEA-gamma-Glu-C20 diacid)-AQAibAFIEYLLEGGPSSGAPPPS-NH2
- Molecular mass
- 4731.4 g/mol
- CAS number
- 2381089-83-2
- Molecular formula
- C221H342N46O68
Material record
- Physical appearance
- White to off-white lyophilized powder
- Solubility
- Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
- Product note
- GLP-3 research compound; supplied strictly for research use only.
GHK-Cu · 50 mg
Molecular profile
- Sequence
- Gly-His-Lys
- Molecular mass
- 401.91 g/mol
- CAS number
- 89030-95-5
- Molecular formula
- C14H22CuN6O4
Material record
- Physical appearance
- Blue to blue-green lyophilized powder
- Salt form
- 1:1 GHK–Cu(II) complex
- Solubility
- Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
- Product note
- Copper-binding tripeptide complex; supplied strictly for research use only.
Bacteriostatic Water · 10 ml
Molecular profile
- Molecular mass
- Water: 18.015 g/mol; benzyl alcohol: 108.14 g/mol.
- CAS number
- Water: 7732-18-5; benzyl alcohol: 100-51-6.
- Molecular formula
- Water: H2O; benzyl alcohol: C7H8O.
Material record
- Physical appearance
- Clear, colourless aqueous solution.
- Solubility
- Aqueous solution; miscible with water.
- Product note
- Aqueous laboratory solvent formulation containing 0.9% benzyl alcohol preservative with a pH range of 4.5–7.0; supplied strictly for research and laboratory use.
The research behind the combination
A clear starting point for complementary research
Starter connects two different research questions in one convenient selection. Retatrutide is studied across GLP-1, GIP and glucagon receptor systems; GHK-Cu adds a copper-peptide perspective on extracellular-matrix responses. Together in the same research collection, they support a broader study design than a selection focused on a single receptor family.
The value of the pairing is its complementary scope. A laboratory can investigate metabolic signalling alongside matrix-related endpoints while keeping the materials separately identified. Each vial retains its own compound, strength and report, so the bundle does not obscure what is being studied.
The ready-made selection includes the displayed quantities and BAC Water, with the full component value and bundle saving shown together. It is a practical starting point when you want a coherent research theme, clear contents and less ordering work.
- Two complementary research directions
- Clearly identified individual vials
- BAC Water included in the displayed value
Explore the individual components
Retatrutide · 10 mg
Description of GLP-3
GLP-3 is a synthetic peptide that acts as a triple agonist of the GCG-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and GCG receptors. This combinatorial receptor signaling enables simultaneous modulation of multiple metabolic pathways. In contrast to earlier GLP-1 receptor agonists, which primarily target appetite suppression and glycemic improvement, GLP-3 leverages GCG receptor activation to stimulate lipolysis and elevate basal metabolic rate, thereby contributing to a more pronounced and sustained reduction in adiposity as observed in research models.
The GLP-1 and GIP receptors play essential roles in augmenting insulin secretion and glucose homeostasis, whereas GCG receptor engagement elevates circulating GCG levels, promoting catabolic processes. Through this triagonist mechanism, GLP-3 has been observed in studies to reduce caloric intake and influence glycemic control while also affecting energy expenditure. This comprehensive modulation of energy balance represents a novel research strategy in the investigation of obesity, type 2 diabetes, and related metabolic disorders.
Key Research Findings
- Triple Receptor Activation: Simultaneous stimulation of GLP-1, GIP, and Glucagon receptors for enhanced metabolic efficiency.
- Appetite & Energy Regulation: Influences central mechanisms of appetite control and promotes caloric expenditure.
- Glucose & Lipid Metabolism: Supports improved insulin sensitivity, glucose homeostasis, and fat oxidation.
- Body Composition: Studied for its potential to reduce body fat while preserving lean mass.
Why Choose Retatrutide?
- Retatrutide is one of the most advanced multi-agonist peptides currently under investigation.
- Through its synergistic activation of GLP-1, GIP, and Glucagon receptors, it provides unique insights into the hormonal regulation of energy balance, fat metabolism, and appetite control.
Order Retatrutide and explore its potential in the next generation of metabolic and weight management research.
Overview of Published Research:
GLP-3 represents a novel generation of research compounds in the anti-obesity and antidiabetic field, characterized by its unique mechanism of action involving the simultaneous activation of three metabolically relevant receptors: the GCG-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the GCG receptor (GCGR). This triple agonism allows for an integrated modulation of key pathways regulating body weight and metabolic homeostasis. GLP-1 and GIP are incretin hormones that have been shown to influence insulin secretion, appetite, and glycemic control, while GCG primarily stimulates lipolysis, increases energy expenditure, and promotes fatty acid oxidation. As a synthetic peptide with an extended half-life, GLP-3 consolidates these effects into a once-weekly injectable formulation studied in clinical trials.
The activity of GLP-3 has been evaluated in several randomized phase 2 clinical trials, demonstrating significant weight reduction. After 48 weeks of treatment, participants receiving 8 mg and 12 mg doses experienced a mean body weight reduction of 22.8% and 24.2%, respectively—an outcome comparable to bariatric surgery. Additional observations included decreases in body mass index (BMI), waist circumference, fasting plasma glucose, HbA1c, and blood pressure. These effects were dose-dependent and particularly pronounced at higher doses. Notably, GLP-3 also exerted a substantial impact on hepatic steatosis, with liver fat volume reduced by up to 82.4% at 12 mg after 24 weeks. A considerable proportion of participants achieved a liver fat content below the threshold for steatosis (<5%), indicating research promise for metabolic liver diseases such as nonalcoholic steatohepatitis (NASH).
Given the high global prevalence of obesity and its strong association with type 2 diabetes and other chronic diseases, GLP-3 emerges as a highly promising research candidate. Ongoing phase 3 trials aim to further establish its long-term safety profile and observed activity. If positive, GLP-3 may be positioned as one of the most significant research innovations in the obesity field in recent decades.
Recent phase 2 clinical trial data evaluating the activity and safety of GLP-3 in subjects with type 2 diabetes demonstrate its pronounced effects on both glycemic control and body weight reduction. In one of the studies, patients with a mean baseline body mass index (BMI) of 35.3 kg/m² and an average HbA1c of 8.3% were randomized to receive varying doses of GLP-3 (ranging from 1 mg to 12 mg) or placebo over a 36-week study period. GLP-3 exhibited a clear dose-dependent reduction in HbA1c, with the highest dose (12 mg) achieving a mean HbA1c reduction of 2.16 percentage points from baseline, compared to only 0.43% in the placebo group—an effect that was statistically highly significant.
In addition to glycemic changes, a substantial reduction in body weight was also observed. Participants receiving the 12 mg dose of GLP-3 experienced a weight loss of up to 16.94%, corresponding to approximately 17.5 kg, while the placebo group showed a reduction of only 3.29%. The weight loss was consistent throughout the study period and showed a continued downward trend beyond week 36, suggesting a potential for sustained long-term activity. These findings highlight the dual observations with GLP-3 in subjects with type 2 diabetes, combining pronounced glucose-lowering effects with notable anti-obesity properties—particularly relevant given the strong association between obesity, insulin resistance, and impaired glycemic control.
GLP-3, as a triple agonist targeting GLP-1, GIP, and GCG receptors, holds significant promise as a research compound in the investigation of type 2 diabetes—not only through its observed influence on glycemic parameters but also via its substantial impact on weight reduction. Its activity in diabetic study populations approaches outcomes observed in individuals with obesity without diabetes, indicating its potential as a next-generation subject of investigation. These results may inform further research into more individualized approaches in subjects with diabetes and metabolic syndrome, especially in those with significant overweight or obesity.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most prevalent chronic liver disorder worldwide, with an increasing incidence driven by the global rise in obesity and metabolic syndrome. Pathophysiologically, MASLD is strongly associated with insulin resistance, leading to hepatic lipid accumulation, inflammation, and in advanced stages, fibrosis and cirrhosis.
GLP-3, a novel triple agonist of the GIP, GLP-1, and GCG receptors, has demonstrated significant hepatoprotective effects in research involving individuals with MASLD. In a phase 2 substudy that included participants with hepatic fat content ≥10%, 48-week administration of GLP-3 resulted in a robust, dose-dependent reduction in liver fat. At doses of 8 mg and 12 mg, participants achieved a mean relative reduction in hepatic fat content of 81.4% and 82.4%, respectively, at week 24 (versus +0.3% in the placebo group), with normalization of liver fat content (<5%) observed in 79% and 86% of participants. These effects were sustained at week 48, with 89% and 93% of participants maintaining hepatic fat levels below the steatosis threshold. Additionally, liver volume decreased significantly, and improvements were observed in biomarkers of hepatic injury and inflammation, suggesting potential antifibrotic and anti-inflammatory properties in these models.
The hepatic effects of GLP-3 are likely mediated by multiple mechanisms. Most prominently, the substantial reduction in total and visceral adiposity is tightly linked to improved insulin sensitivity—a core pathophysiological determinant of MASLD. Enhanced insulin action decreases the influx of free fatty acids to the liver and suppresses hepatic de novo lipogenesis. Moreover, administration of GLP-3 resulted in favorable changes in metabolic parameters including glycemia, lipid profile, and inflammatory markers. Given the current lack of approved research compounds for metabolic dysfunction-associated steatohepatitis (MASH)—the progressive form of MASLD characterized by hepatocellular injury and fibrosis—GLP-3 emerges as a highly promising research candidate. Its multifaceted mechanism of action, encompassing weight reduction, metabolic normalization, and marked hepatic fat clearance, underscores its potential role in the further investigation of metabolic liver diseases.
For laboratory purposes and personal observation only. Not for human consumption.
GHK-Cu · 50 mg
Description of GHK-Cu
The human copper-binding peptide GHK-Cu (glycyl-l-histidyl-l-lysine) is a naturally occurring tri-peptide found in human plasma and released from tissues during injury. Discovered in 1973, GHK-Cu has established itself as a extensively studied protective and regenerative compound, widely used in skin and hair products. In research and cosmetic contexts, GHK-Cu has been associated with tightening loose skin, repairing protective skin barrier proteins, and improving skin firmness, elasticity, and clarity. It has been studied in relation to fine lines, wrinkles, and photodamage, and smoothing rough skin. Additionally, GHK-Cu has been investigated for its role in wound healing, protection of skin cells from UV radiation, reduction of inflammation and free radical damage, and enhancement of hair growth and thickness. Its effects are largely attributed to its ability to bind copper(II) ions, playing a crucial role in copper metabolism. Recent research, utilizing the Connectivity Map from the Broad Institute, has shown that GHK-Cu can up- and down-regulate numerous human genes, linking its biological effects to changes in gene expression.
Mechanism of Action
GHK-Cu binds copper ions and incorporates them into regenerative metabolic pathways, activating:
- Collagen Synthesis → Promotes tissue rebuilding, skin firmness, and scar repair
- Angiogenesis → Supports new blood vessel formation for improved tissue healing
- Antioxidant Enzymes → Protects against free radicals and cellular stress
- Gene Regulation → Activates over 4,000 genes involved in healing, anti-inflammation, and anti-aging processes
Further research on GHK-Cu reveals its presence in human blood plasma, urine, and saliva. Animal studies indicate that GHK-Cu can significantly influence wound healing, immune function, and skin health by stimulating collagen production, promoting blood vessel growth, and supporting fibroblast activity.
Why Choose GHK-Cu?
- GHK-Cu is unique among peptides for its targeted regenerative and anti-aging effects.
- While many peptides focus on fat loss or muscle gain, GHK-Cu directly supports skin, connective tissue, and cellular repair.
- It is one of the most respected peptides in both aesthetic and regenerative medicine research, valued for its safety, biological compatibility, and broad spectrum of action.
Order GHK-Cu and explore its potential in regeneration, skin rejuvenation, and advanced anti-aging research.
Now we would like to bring you closer to the effects of the peptide, which have been researched and confirmed in studies.
Overview of Published Research
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring peptide in human plasma, saliva, and urine that declines with age. Known for its extensively researched protective and regenerative properties, GHK-Cu has been shown to accelerate wound healing and skin repair by stimulating the synthesis and breakdown of collagen, glycosaminoglycans, and other extracellular matrix components. It modulates the activity of metalloproteinases and their inhibitors, promoting the healing of various tissues such as skin, hair follicles, and bones. In cosmetic products, GHK-Cu has been studied in the context of tightening loose skin, improving elasticity and firmness, reducing fine lines, wrinkles, and hyperpigmentation, and enhancing overall skin appearance. Additionally, it has been investigated for potential relevance to conditions like skin inflammation, chronic obstructive pulmonary disease, and metastatic colon cancer, owing to its ability to regulate thousands of human genes, with observed effects on resetting DNA expression patterns.
Recent studies have highlighted GHK-Cu's role in modulating key growth factors involved in wound healing and skin regeneration. Transforming growth factor β (TGF-β) and insulin growth factor (IGF) are crucial in these processes, with GHK-Cu shown to decrease IGF-2-dependent TGF-β1 secretion in dermal fibroblasts, potentially preventing hypertrophic scar formation. Furthermore, GHK-Cu encapsulated in liposomes has been demonstrated to accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis, enhancing the expression of vascular endothelial growth factor and fibroblast growth factors, and improving the overall healing process. These findings underscore the peptide's potential as a subject of further research in skin regeneration and wound healing.
In vitro studies have highlighted the promising antimicrobial activity of Gly-His-Lys conjugates as candidates for further research into skin and tissue infections. These studies explored novel compounds, including fatty acid conjugates with modified Gly-His-Lys sequences. The antimicrobial efficacy of these compounds ranged from strong to moderate. Notably, compound 1d exhibited the most potent activity against Escherichia coli and Staphylococcus aureus with MIC ranges of 31.3–125.0 μg/mL and against Pseudomonas aeruginosa with MIC ranges of 375.0–500.0 μg/mL. Conjugate 5b showed significant activity against Staphylococcus aureus and Escherichia coli at MIC ranges of 250.0–500.0 μg/mL and 62.5–125.0 μg/mL, respectively. Both 1d and 5b demonstrated rapid bactericidal effects against Gram-positive bacteria. Additionally, compounds 1d, 1e, and 2e showed notable antifungal activity.
A multicenter, randomized, evaluator-blinded, placebo-controlled clinical study evaluated the effectiveness of the glycyl-L-histidyl-L-lysine copper complex (lamin Gel) in treating diabetic neuropathic ulcers. Patients adhered to a standardized wound care protocol, including sharp debridement, daily drug application, pressure-relieving footwear, and diabetes management education. Treatment with lamin Gel significantly improved ulcer closure rates, achieving a median area closure of 98.5% compared to 60.8% for the control group. The rate of closure was three times faster with lamin Gel, particularly for larger ulcers (greater than 100 mm²), which showed an 89.2% closure compared to -10.3% for the control. Immediate treatment post-debridement was crucial for optimal results. Additionally, the incidence of ulcer infections was significantly lower in the lamin Gel group (7%) compared to the control (34%).
An experimental study on the effects of topical glycyl-L-histidyl-L-lysine tripeptide-copper complex (TCC) on ischemic open wounds in rats further supported the observed activity of GHK-Cu. Rats treated with TCC showed a significant decrease in wound area compared to control and vehicle groups. By day 13, the TCC group exhibited a 64.5% reduction in wound area, outperforming the vehicle (45.6%) and control (28.2%) groups. TCC-treated wounds also had significantly lower concentrations of TNF-alpha and MMP-2 and MMP-9, indicating reduced inflammation and enhanced healing. These findings suggest that TCC could be of research interest as an approach for chronic wounds in various species, including humans.
Overall, GHK-Cu has shown notable results in research models of diabetic ulcers and ischemic open wounds compared to standard care alone. Its combination with certain fatty acids creates a potent antimicrobial compound with activity against bacteria and fungi, with observed reductions in infection rates and acceleration of wound healing. These findings warrant further research evaluation of GHK-Cu in the context of wound care.
Neurodegeneration, characterized by the progressive death of neurons and cognitive decline, is a growing concern among senior populations, with limited effective research approaches available. One compound of research interest is the human peptide GHK (glycyl-L-histidyl-L-lysine), a copper-binding peptide known for its diverse biological actions that have been studied in the context of aging-related diseases and conditions. GHK has shown effects on various tissues, including chondrocytes, liver cells, and human fibroblasts, as documented in research. Importantly, studies using the Broad Institute Connectivity Map have demonstrated that GHK can modulate gene expression, with observed effects on resetting pathological patterns toward healthier states.
In research focused on the nervous system, GHK has demonstrated neuroprotective effects in models of neurodegenerative diseases and improved tissue regeneration. A study on rats with intracerebral hemorrhage (ICH) revealed that GHK pretreatment significantly improved neurological deficits, reduced brain water content, and inhibited neuronal apoptosis. The peptide's effects were mediated through the downregulation of miR-339-5p expression, which was found to be part of the p38 MAPK pathway. Additionally, GHK's influence on the miR-339-5p/VEGFA axis played a crucial role in preventing neuronal apoptosis following ICH injury. These findings suggest that GHK could represent a novel area of research investigation for conditions like ICH.
GHK-Cu, a variant of the peptide found in high concentrations in the brain, has been studied for its ability to counteract age-associated decline in neuron function. Research indicates that GHK-Cu influences angiogenesis in the nervous system, nerve outgrowth, and central nervous system inflammation. It appears to reset pathological gene expression, with observed effects on restoring function in dysfunctional systems. In rat models, GHK-Cu's neuroprotective effects were evident through improved neurological deficits, reduced brain swelling, and inhibition of neuron death. These effects were particularly notable in the context of overexpression of miR-339-5p following brain injuries such as bleeds and strokes, underscoring GHK-Cu's potential as a research subject in the context of neurodegeneration.
GHK peptide shows promise in inhibiting bleomycin-induced pulmonary fibrosis in mice by suppressing the TGF-β1/Smad-mediated epithelial-to-mesenchymal transition (EMT). Pulmonary fibrosis, an irreversible and progressive lung disease, lacks effective treatments. It occurs after therapy with bleomycin – cancer drug. GHK, a tripeptide known for its role in tissue regeneration and wound healing, was tested for its effects on bleomycin-induced fibrosis. Mice were administered GHK intraperitoneally at various doses following bleomycin instillation. Results demonstrated that GHK treatment reduced inflammatory cell infiltration, improved collagen deposition, and balanced MMP-9/TIMP-1 levels. It also decreased TNF-α, IL-6 in bronchoalveolar lavage fluid, and myeloperoxidase activity in lung extracts. GHK further inhibited TGF-β1, p-Smad2, p-Smad3, and IGF-1 expression, indicating its potential as a subject of further research in pulmonary fibrosis by targeting the TGF-β1/Smad 2/3 and IGF-1 pathways.
GHK-Cu, the copper-bound form of the peptide, also exhibits protective effects against lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice. GHK-Cu treatment reduced reactive oxygen species (ROS) production, increased superoxide dismutase (SOD) activity, and decreased TNF-α and IL-6 production by inhibiting NF-κB p65 and p38 MAPK signaling in LPS-induced macrophages and ALI models. This treatment alleviated lung histological alterations and suppressed inflammatory cell infiltration, demonstrating GHK-Cu's potential as a novel research subject for ALI and acute respiratory distress syndrome (ARDS) by mitigating excessive inflammatory responses.
Research highlights the observed activity of GHK-Cu in protecting lungs from fibrosis following bleomycin therapy, suggesting its potential interest as a chemotherapy adjuvant research subject to investigate increased medication doses without exacerbating side effects. GHK-Cu regulates inflammatory molecules TNF-α and IL-6, with observed effects on fibrotic remodeling and collagen deposition in the lungs. Similarly, GHK-Cu showed notable findings in mouse models of ARDS, reducing TNF-α and IL-6 expression, and demonstrating a protective effect against this rapid and potentially fatal inflammatory lung condition. These findings support further research into GHK-Cu in the context of various lung injuries and diseases.
GHK-Cu exhibits promising analgesic and anti-aggressive effects in rat models, particularly in response to pain-induced aggressive-defensive behavior. Administered intraperitoneally in doses ranging from 5 to 150 μg/kg, GHK-Cu demonstrated significant pain relief and reduction in aggressive behavior in a foot-shock model. The key to these effects lies in the L-lysine residue within the GHK peptide, as similar analgesic and anti-aggressive effects were observed with L-lysine administration at equivalent doses.
Furthermore, the peptide's activity extends to interactions with L-arginine, another amino acid with analgesic properties. Research has shown that combining arginine with glyprolines to form specific peptides can produce intrinsic regulatory effects on pain and aggression. This suggests that GHK-Cu and related peptides could be investigated as potential non-addictive research alternatives in the context of pain management, alongside opiate medications and NSAIDs, which are known for their potential side effects, including negative impacts on cardiovascular health. These findings highlight the research interest of GHK-Cu in pain-related studies, opening a potential avenue for developing safer pain relief approaches.
Bacteriostatic Water · 10 ml
Bacteriostatic Water (BW) is a sterile, pyrogen-free solution used as a solvent for the reconstitution of lyophilized research peptides and laboratory compounds.
It contains 0.9% benzyl alcohol, which acts as a bacteriostatic preservative that inhibits bacterial growth, allowing the solution to remain stable under sterile conditions for multiple withdrawals.
Key Features
- Sterile & Pyrogen-Free: Safe for laboratory use in peptide reconstitution.
- With Benzyl Alcohol: Inhibits bacterial growth for extended usability after opening.
- Compatibility: Suitable for all common lyophilized peptides and lab compounds.
Laboratory care
Handling
Peptides in transport
Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.
Storage of lyophilized peptides
Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Up to 3 months
- Refrigerated (2–8 °C): Up to 6 months
- Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)
Allow the vial to reach room temperature after taking it out of the refrigerator or freezer.
Storage of reconstituted peptides
Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.
The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Avoid prolonged storage
- Refrigerated (2–8 °C): Typically 4–8 weeks
- Frozen (-20 °C or below): Up to 3–4 months
To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.
Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.
Bacteriostatic Water
Product is designed as diluent for reconstitution of lyophilised peptides. The product is intended for scientific research and development purposes only. Chemical substances shall not be used as a drug, medicine, active substance, medical aid, cosmetic product, a substance for production of a cosmetic product neither for human consumption that is any food or food supplement or otherwise similarly used on humans or animals. Use for research and scientific purposes only. Do not use for diagnostic or therapeutic purposes or as medical device.
Storage
Should be stored at room temperature and protected from direct light, excessive heat and freezing.
Reports for the included vial strengths
Tests
Retatrutide · 10 mg
Latest published result
Liquilabs s.r.o.Signed Certificate of Analysis · 10mg
99.4%Purity by HPLC
Recorded QC panel
- AssayPeptide screening
- 9.78 mg
- PurityPeptide screening
- 99.4%
- Identity (FTIR)FTIR spectrum
- 994
- Identity (RT)Retention time
- 0.995
- Bacterial EndotoxinUSP / Eur. Ph. 2.6.14
- 0.082 EU/mg
- Molecular Ion MassMS deconvolution
- 4731 Da
These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.
GHK-Cu · 50 mg
Latest published result
Liquilabs s.r.o.Signed Certificate of Analysis · 50mg
> 99.8%Purity by HPLC
Recorded QC panel
- AssayPeptide screening
- 44.4 mg
- PurityPeptide screening
- > 99.8%
- Identity (FTIR)FTIR spectrum
- 987
- Identity (RT)Retention time
- 1.000
- Bacterial EndotoxinUSP / Eur. Ph. 2.6.14
- 0.004 EU/mg
- Molecular Ion MassMS deconvolution
- 341 Da
These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.
Bacteriostatic Water · 10 ml
Documentation is available on request
Contact us for the current record for this strength. We never substitute a generic or mismatched certificate.
Your batch is confirmed when your order is allocated.Research sources
References
- Jastreboff et al., 2023 · retatrutide receptor research
- Maquart et al., 1993 · copper peptide and connective tissue
Research references concern individual compounds and experimental models. They do not establish combined efficacy of these packaged selections.
Retatrutide · 10 mg
„Retatrutide (LY3437943): A Novel Tri-agonist Peptide for Metabolic Disease Treatment", 2025.
Alaa Abdrabou Abouelmagd et al., „Efficacy and safety of retatrutide, a novel GLP-1, GIP, and GCG receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials", 2025.
Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GCG, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247.e9. doi: 10.1016/j.cmet.2022.07.013. [DOI] [PubMed]
Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037–2048. doi: 10.1038/s41591-024-03018-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial. N Engl J Med. 2023;389(6):514–526. doi: 10.1056/NEJMoa2301972. [DOI] [PubMed]
Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and GCG receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. doi: 10.1016/S0140-6736(23)01053-X. [DOI] [PubMed]
Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and GCG receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. doi: 10.1016/S0140-6736(22)02033-5. [DOI] [PubMed]
Coskun T, Urva S, Roell WC, et al. · 2022
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Discovery, molecular design, and receptor characterisation of LY3437943.
Cell Metabolism · 10.1016/j.cmet.2022.07.013 View source ↗Jastreboff AM, Kaplan LM, Frías JP, et al. · 2023
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Clinical research report concerning the compound described as retatrutide.
The New England Journal of Medicine · 10.1056/nejmoa2301972 View source ↗National Center for Biotechnology Information
PubChem Compound Summary: Retatrutide
Authoritative identity record for retatrutide, also described as LY3437943.
PubChem View source ↗Goldney J, Hamza M, Surti F, Davies MJ, Papamargaritis D · 2025
Triple Agonism Based Therapies for Obesity
Current cardiovascular risk reports View source ↗Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K · 2025
Retatrutide-A Game Changer in Obesity Pharmacotherapy
Biomolecules View source ↗Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, Abdelsalam F, Marey A, Tanas Y, Abuklish DM, Belal MM · 2025
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
Proceedings (Baylor University. Medical Center) View source ↗· 2025
Retatrutide (LY3437943): A Novel Tri-agonist Peptide for Metabolic Disease Treatment
2025Alaa Abdrabou Abouelmagd et al. · 2025
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and GCG receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
2025· 2024
Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037–2048. doi: 10.1038/s41591-024-03018-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
· 10.1038/s41591-024-03018-2 View source ↗· 2023
Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and GCG receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. doi: 10.1016/S0140-6736(23)01053-X. [DOI] [PubMed]
· 10.1016/s0140-6736(23)01053-x View source ↗· 2022
Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and GCG receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. doi: 10.1016/S0140-6736(22)02033-5. [DOI] [PubMed]
· 10.1016/s0140-6736(22)02033-5 View source ↗GHK-Cu · 50 mg
L. Pickart, J. M. Vasquez-Soltero, and A. Margolina, "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration," BioMed Res. Int., vol. 2015, p. 648108, 2015. [BioMed Research International]
A. Gruchlik, E. Chodurek, and Z. Dzierzewicz, "Effect of GLY-HIS-LYS and its copper complex on TGF-β secretion in normal human dermal fibroblasts," Acta Pol. Pharm., vol. 71, no. 6, pp. 954–958, Dec. 2014. [PubMed]
L. Pickart and A. Margolina, "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data," Int. J. Mol. Sci., vol. 19, no. 7, Jul. 2018. [PubMed]
X. Wang et al., "GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis," Wound Repair Regen. Off. Publ. Wound Heal. Soc. Eur. Tissue Repair Soc., vol. 25, no. 2, pp. 270–278, 2017. [PubMed]
M. Kukowska, M. Kukowska-Kaszuba, and K. Dzierzbicka, "In vitro studies of antimicrobial activity of Gly-His-Lys conjugates as potential and promising candidates for therapeutics in skin and tissue infections," Bioorg. Med. Chem. Lett., vol. 25, no. 3, pp. 542–546, Feb. 2015. [Science Direct]
G. D. Mulder et al., "Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper," Wound Repair Regen. Off. Publ. Wound Heal. Soc. Eur. Tissue Repair Soc., vol. 2, no. 4, pp. 259–269, Oct. 1994. [PubMed]
S. O. Canapp et al., "The effect of topical tripeptide-copper complex on healing of ischemic open wounds," Vet. Surg. VS, vol. 32, no. 6, pp. 515–523, Dec. 2003. [PubMed]
L. Pickart, J. M. Vasquez-Soltero, and A. Margolina, "The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline," Brain Sci., vol. 7, no. 2, Feb. 2017. [PubMed]
H. Zhang, Y. Wang, and Z. He, "Glycine-Histidine-Lysine (GHK) Alleviates Neuronal Apoptosis Due to Intracerebral Hemorrhage via the miR-339-5p/VEGFA Pathway," Front. Neurosci., vol. 12, p. 644, 2018. [PubMed]
X.-M. Zhou et al., "GHK Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice by Suppressing TGFβ1/Smad-Mediated Epithelial-to-Mesenchymal Transition," Front. Pharmacol., vol. 8, p. 904, 2017. [PubMed]
J.-R. Park, H. Lee, S.-I. Kim, and S.-R. Yang, "The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice," Oncotarget, vol. 7, no. 36, pp. 58405–58417, Sep. 2016. [PubMed]
L. А. Sever'yanova and M. E. Dolgintsev, "Effects of Tripeptide Gly-His-Lys in Pain-Induced Aggressive-Defensive Behavior in Rats," Bull. Exp. Biol. Med., vol. 164, no. 2, pp. 140–143, Dec. 2017. [Springer]
L. А. Sever'yanova and D. V. Plotnikov, "Binding of Glyprolines to L-Arginine Inverts Its Analgesic and Antiagressogenic Effects," Bull. Exp. Biol. Med., vol. 165, no. 5, pp. 621–624, Sep. 2018. [PubMed]
Badenhorst T, Svirskis D, Merrilees MJ, et al. · 2016
Physicochemical characterization of native glycyl-l-histidyl-l-lysine tripeptide for wound healing and anti-aging: a preformulation study for dermal delivery
Physicochemical and stability characterisation of GHK-Cu.
Pharmaceutical Development and Technology · 10.3109/10837450.2014.979944 View source ↗National Center for Biotechnology Information
PubChem Compound Summary: GHK-Cu
Authoritative identity record for the GHK-Cu copper-peptide complex.
PubChem View source ↗Chemical Abstracts Service
CAS Common Chemistry: 49557-75-7
Authoritative CAS Registry Number record for GHK-Cu.
CAS Common Chemistry View source ↗National Center for Biotechnology Information
PubChem compound record
PubChem View source ↗Pickart L, Margolina A · 2018
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
International journal of molecular sciences View source ↗Pickart L, Vasquez-Soltero JM, Margolina A · 2015
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
BioMed research international View source ↗A. Gruchlik, E. Chodurek, and Z. Dzierzewicz · 2014
Effect of GLY-HIS-LYS and its copper complex on TGF-β secretion in normal human dermal fibroblasts
Acta Pol. PharmX. Wang et al. · 2017
GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis
Wound Repair Regen. Off. Publ. Wound Heal. Soc. Eur. Tissue Repair SocM. Kukowska, M. Kukowska-Kaszuba, and K. Dzierzbicka · 2015
In vitro studies of antimicrobial activity of Gly-His-Lys conjugates as potential and promising candidates for therapeutics in skin and tissue infections
Bioorg. Med. Chem. LettG. D. Mulder et al. · 1994
Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper
Wound Repair Regen. Off. Publ. Wound Heal. Soc. Eur. Tissue Repair SocS. O. Canapp et al. · 2003
The effect of topical tripeptide-copper complex on healing of ischemic open wounds
Vet. Surg. VSL. Pickart, J. M. Vasquez-Soltero, and A. Margolina · 2017
The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline
Brain SciH. Zhang, Y. Wang, and Z. He · 2018
Glycine-Histidine-Lysine (GHK) Alleviates Neuronal Apoptosis Due to Intracerebral Hemorrhage via the miR-339-5p/VEGFA Pathway
Front. NeurosciX.-M. Zhou et al. · 2017
GHK Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice by Suppressing TGFβ1/Smad-Mediated Epithelial-to-Mesenchymal Transition
Front. PharmacolJ.-R. Park, H. Lee, S.-I. Kim, and S.-R. Yang · 2016
The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice
OncotargetL. А. Sever'yanova and M. E. Dolgintsev · 2017
Effects of Tripeptide Gly-His-Lys in Pain-Induced Aggressive-Defensive Behavior in Rats
Bull. Exp. Biol. MedL. А. Sever'yanova and D. V. Plotnikov · 2018
Binding of Glyprolines to L-Arginine Inverts Its Analgesic and Antiagressogenic Effects
Bull. Exp. Biol. MedBacteriostatic Water · 10 ml
National Center for Biotechnology Information
PubChem Compound Summary: Benzyl alcohol
Authoritative identity record for the preservative component of Bacteriostatic Water.
PubChem View source ↗Chemical Abstracts Service
CAS Common Chemistry: 7732-18-5
Authoritative CAS Registry Number record for water.
CAS Common Chemistry View source ↗Chemical Abstracts Service
CAS Common Chemistry: 100-51-6
Authoritative CAS Registry Number record for benzyl alcohol.
CAS Common Chemistry View source ↗Customer reviews
Quality products,fast shipping,great refferal plan,only downside is that products in 4 mounths since my first order got more and more expensive ,but overall verry good experience.
Read full review →More than 2 weeks for package dispatch. They promised one free peptide next time. Sent me new tracking number but package still wasn't delivered to fedex. Last package (much much cheaper) was delivered in less than week. I will update if they will send my package. ok,package sent.
Read full review →Extremely satisfied with the product quality and overall experience. The customer service is polite and quick. All recommendations!
Read full review →Great service!
Read full review →Always on time and customer care is super great
Read full review →Fast good, and quality is perfect
Read full review →ordered 3 times now and everything ok every time.
Read full review →Trustworthy site with a huge catalog of products. Been purchasing from them for some time now never got disappointed. I could only recommend them.
Read full review →Great quality product
Read full review →Everything was great, super customer support, honest, reliable
Read full review →Everything ok. With little problem with package, but after contact with Customer Service everything went right. Good quality of products
Read full review →Excellent. Buying peptides online can be nerve wracking! But Adria are very transparent about all the checks and certifications. My experience with them was excellent. Great products at good prices and efficient P&P
Read full review →





